Oasmia is a specialty pharmaceutical company dedicated to improving the lives of patients by enhancing the intravenous delivery of established and novel drugs in significant diseases, in several indications, including cancer.

Oasmia Pharmaceutical published its interim report for the second quarter of 2021 on August 19, 2021, at 08.00 am CEST.

The company will hold a conference call and an online presentation on the same day at 10.00 am CEST. The call will be hosted by CEO Francois Martelet and CFO Fredrik Järrsten. The presentation will be in English.

The Share